GAINESVILLE, Fla.--(BUSINESS WIRE)--Exactech, a developer and producer of innovative implants, instrumentation and smart technologies for joint replacement is proud to announce a preferred relationship with Permedica S.p.A. to distribute hip...
MONTREAL, Feb. 11, 2022 /PRNewswire/ - Ortho Regenerative Technologies Inc. (CSE: ORTH) (OTC: ORTIF) ("Ortho" or the "Company"), a clinical-stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, announced...
Studies Highlight Exactech Active Intelligence® Smart Solutions for Joint Replacement. GAINESVILLE, Fla.--(BUSINESS WIRE)--Exactech, a developer and producer of innovative implants, instrumentation and smart technologies for joint replacement surgery, announced today that...
JAZZ™ PF: a simple, innovative and proprietary addition to the JAZZ® rangeAddressable annual market of almost $350 million in the United States1 BORDEAUX, France & BOSTON--(BUSINESS WIRE)--Regulatory News: IMPLANET (Paris:ALIMP) (Euronext Growth: ALIMP,...
LONDON, Feb. 10, 2022 /PRNewswire/ -- Smith+Nephew (LSE:SN,NYSE:SNN), the global medical technology business, today announces the first completed surgery using its JOURNEY II Medial Dished (MD) System for total knee arthroplasty (TKA)....
Innovative Elective Foot & Ankle Products Will Provide Surgeons with Multiple Options to Address Growing Patient Need WEST CHESTER, PA – February 10, 2022 – Today, the Johnson & Johnson Medical Devices...
(Memphis, TN) February 10, 2022 – MB Venture Partners (“MBVP”) is very pleased to announce the sale of it’s portfolio company, Memphis-based CrossRoads Extremity Systems (“CrossRoads”, or the “Company”) to...
- New Patent will Strengthen Company’s IP Portfolio - CARLSBAD, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a designer...
MONTREAL, Feb. 7, 2022 /PRNewswire/ - Ortho Regenerative Technologies Inc. (CSE: ORTH) (OTC: ORTIF) ("Ortho" or the "Company"), a clinical-stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, today...
- Fourth quarter net sales of $2.038 billion decreased 2.3% and 0.8% on a constant currency[1] basis - Fourth quarter diluted loss per share was $0.40; adjusted[1] diluted earnings per share...